Auspex is developing SD-809, a deuterium substituted version of the established neurological drug tetrabenazine as a treatment for Huntington’s disease and other movement disorders. We believe ...
JERUSALEM & LA JOLLA, Calif.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), today announced that they have entered into a ...
Auspex Pharmaceuticals announced today that the first patient has been enrolled in a multi-center Phase 3 pivotal trial of its lead investigational drug, SD-809 for the treatment of involuntary ...
LA JOLLA, Calif., Oct. 17, 2013 /PRNewswire/ -- Auspex Pharmaceuticals, Inc., a privately-held clinical stage biopharmaceutical company focused on developing innovative therapeutics for the treatment ...
San Diego’s Auspex Pharmaceuticals has agreed to a $3.2 billion purchase by Israeli drug maker Teva Pharmaceutical, the companies said in a joint statement Monday. The purchase, expected to close by ...
Teva Pharmaceutical Industries Ltd. agreed to buy Auspex Pharmaceuticals Inc. for about $3.5 billion in cash to gain drugs that curb tics and other movement disorders. Teva will begin a tender offer ...
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments. Jerusalem-based Teva ...
That’s because Auspex was founded and is run by former Cambridge Analytica staff. Their new data analysis company claims to be “ethically based” and offers “boutique geopolitical consultancy” services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results